CHINESE JOURNAL OF DRUG EVALUATION >

2025 , Vol. 42 >Issue 6: 469 - 469-476

DOI: https://doi.org/magtech-2025-05-08-00002

A Comprehensive Clinical Evaluation of Desonide Cream in the Treatment of Eczematous Dermatoses

  • Wen-Na LU
Expand
  • 1.Graduate School of Bengbu Medical University， Anhui Bengbu 233000， China；
    2.The First Affiliated Hospital of USTC Anhui Provincial Hospital， Anhui Hefei 230000， China

Received date: 2025-05-08

  Revised date: 2025-10-02

  Accepted date: 2026-01-07

  Online published: 2026-01-07

Fold

Abstract

Objective： To establish a comprehensive clinical evaluation system for desonide cream in the treatment of eczema and dermatitis-like skin diseases， providing evidence-based support for drug policy formulation and clinical application. Methods： Based on the Health Technology Assessment (HTA) framework， evidence from pre-marketing and post-marketing stages was integrated across six dimensions： safety， efficacy， economy， innovation， suitability， and accessibility. Systematic searches of Chinese and English databases were conducted using evidence-based medicine evaluation methods， with R software employed for Meta-analysis. Cost-effectiveness analysis was applied to assess economic value， and clinical value was determined through horizontal comparison with similar drugs such as hydrocortisone. Results： Safety： Pre-marketing animal studies and Phase Ⅱ/Ⅲ clinical trials indicated no significant adverse effects to animals or human subjects. Post-marketing clinical studies demonstrated comparable safety and efficacy between desonide cream and hydrocortisone butyrate cream. Meta-analysis showed a lower incidence of adverse reactions with desonides (3.26%) than hydrocortisone (4.78%)， confirming its favorable safety profile. Efficacy： Pre-marketing pharmacodynamic studies revealed that desonide exhibits stronger activity than hydrocortisone and prednisolone. Phase Ⅱ/Ⅲ trials demonstrated considerable therapeutic effects， and post-marketing Meta-analysis indicated a higher total effective rate for desonide in treating eczema and dermatitis (RR=1.13 [1.05-1.22]) compared to hydrocortisone， confirming superior efficacy. Economy： Pharmacoeconomic analysis based on randomized controlled trials (RCT) showed that the incremental cost-effectiveness ratio (ICER) of desonide cream was below the per ca pita GDP. The additional cost for treating atopic dermatitis was fully justified， demonstrating cost-effectiveness advantages. The daily treatment cost was 0.7 CNY， with course expenses accounting for ≤0.1% of per ca pita disposable income， indicating high affordability. Innovation： Desonide cream is suitable for sensitive areas such as the facial skin of children， filling a clinical gap and exhibiting notable innovation value. Accessibility： The packaging complies with national standards， and the formulation， transportation， shelf life， indications， and administration are well-suited. Listed as a Class B medical insurance product with proportional reimbursement， desonide cream reducing patient financial burden. It is widely available across 31 provinces with sufficient supply， ensuring high accessibility. Conclusion： This study demonstrates that desonide cream exhibits a three-dimensional advantage of “high efficacy， low risk， and economic rationality” in treating eczema and dermatitis-like skin diseases， underscoring its significant clinical value.

Key words： ; font-size:medium; "> ; Desonide Cream； Atopic Dermatitis； Comprehensive Clinical Evaluation

Cite this article

Wen-Na LU . A Comprehensive Clinical Evaluation of Desonide Cream in the Treatment of Eczematous Dermatoses[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2025 , 42(6) : 469 -469-476 . DOI: magtech-2025-05-08-00002

References

  [1] 中华医学会皮肤性病学分会免疫学组，中国医师协会皮肤科医师分会指南制定与规范委员会，宋志强等. 皮炎湿疹类疾病规范化诊断术语专家共识[J]. 中华皮肤科杂志，2021，54(11)：937-942.
     [2] 顾恒，尤立平，刘永生等. 我国10城市学龄前儿童特应性皮炎现况调查[J]. 中华皮肤科杂志，2004，37(1)：29-31.
     [3] Guo Y， Li P， Tang J， et al. Prevalence of atopic dermatitis in Chinese children aged 1-7 ys[J]. Sci Rep， 2016， 6：29751.
     [4] Guo Y， Zhang H， Liu Q， et al. Phenotypic analysis of atopic dermatitis in children aged 1-12 months： elaboration of novel diagnostic criteria for infants in China and estimation of prevalence[J]. J Eur Acad Dermatol Venereol， 2019， 33(8)：1569-1576.
     [5] 中华医学会，中华医学会杂志社，中华医学会皮肤性病学分会等. 儿童特应性皮炎基层诊疗指南(2023年)[J]. 中华全科医师杂志，2023，22(1)：8-18.
     [6] 中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组，中华医学会皮肤性病学分会儿童学组，中国老年保健医学研究会皮肤科分会等. 特应性皮炎外用制剂合理应用及患者指导专家共识[J]. 中华皮肤科杂志，2022，55(4)：281-288.
     [7] 中华医学会，中华医学会杂志社，中华医学会皮肤性病学分会等. 特应性皮炎基层诊疗指南(2022年)[J]. 中华全科医师杂志，2022，21(7)：609-619.
     [8] 顾恒，张建中. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志，2020，53(2)：81-88.
     [9] Phillips BM， Sanen FJ， Leeling JL， et al. The physical， animal and human pharmacologic， and toxicologic properties of desonide， a new， topically active， antiinflammatory steroid[J]. Toxicol Appl Pharmacol， 1971， 20(4)：522-37.
     [10] 孙建方，郑志忠，顾军，等. 0. 05%地奈德乳膏治疗湿疹的多中心随机双盲、对照研究[J]. 中华皮肤科杂志，2006，(1)：26-28.
     [11] Gentry WC Jr， Rosenberg EW， Goltz RW. A clinical evaluation of 0. 05 per cent desonide cream. A new nonfluorinated topical corticosteroid[J]. Arch Dermatol， 1973， 107(6)：870-871.
     [12] 张莉. 地奈德乳膏治疗丘疹性荨麻疹的疗效观察[J]. 当代医学，2023，29(2)：109-111.
     [13] 李凤婷，许丹，陈婷婷. 丁酸氢化可的松软膏与地奈德乳膏治疗湿疹的效果对比[J]. 中国药物滥用防治杂志，2023，29(11)：1963-1965.
     [14] 华颖坚，周富林，张训. 0.05%地奈德乳膏治疗婴儿湿疹的临床疗效观察[J]. 哈尔滨医药，2012，32(2)：119-120.
     [15] 黄启胜. 皮炎湿疹治疗应用地奈德乳膏的临床疗效[J]. 中文科技期刊数据库(文摘版)医药卫生，2023(3)：64-66.
     [16] 申春平，王华，王榴慧等. 地奈德乳膏与丁酸氢化可的松乳膏治疗婴幼儿特应性皮炎的多中心、随机、平行对照临床研究[J]. 中华皮肤科杂志，2019，52(1)：11-15.
     [17] 王宝双. 地奈德乳膏治疗青少年特应性皮炎的临床效果[J]. 中国城乡企业卫生，2022，37(7)：152-154.
     [18] 肖祖鉥. 皮炎湿疹采用地奈德乳膏治疗的临床价值分析[J]. 现代诊断与治疗，2014，25(16)：3715-3716.
Options
Outlines

/

〈 〉

[an error occurred while processing this directive]